Neurotrophic Keratitis Clinical Trial
Official title:
A Double-Masked, Multi-Center, Randomized, Vehicle- Controlled, Phase II Trial of the Efficacy and Safety of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)
The objective of this study is to compare the safety and efficacy of BRM424 OS compared to vehicle in patients with neurotrophic keratitis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04485546 -
Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis
|
Phase 4 | |
| Completed |
NCT04552730 -
Nerve Growth Factor for the Treatment of Cornea Disease
|
||
| Recruiting |
NCT04276558 -
REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
|
Phase 2 | |
| Recruiting |
NCT04573647 -
OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
|
||
| Completed |
NCT04820010 -
Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
|
||
| Recruiting |
NCT04627571 -
Corneal Nerves After Treatment With Cenegermin
|
||
| Enrolling by invitation |
NCT05758753 -
QST for Corneal Nerve Function
|
N/A | |
| Terminated |
NCT05809245 -
Corneal Neurotization as a Treatment for Neurotrophic Keratopathy
|
N/A | |
| Withdrawn |
NCT05321251 -
Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.
|
Phase 2/Phase 3 | |
| Terminated |
NCT03037450 -
Miniinvasive Corneal Neurotization. A Pilot Study.
|
N/A | |
| Not yet recruiting |
NCT06364657 -
Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye
|
||
| Recruiting |
NCT05566717 -
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
|
||
| Not yet recruiting |
NCT02707120 -
Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis
|
Phase 4 | |
| Completed |
NCT01756456 -
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
|
Phase 1/Phase 2 | |
| Completed |
NCT02227147 -
Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
|
Phase 2 | |
| Recruiting |
NCT05552261 -
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
|
||
| Recruiting |
NCT04909450 -
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
|
Phase 1/Phase 2 |